TriangleNCT02998528 · OUTCOME
Overall Survival (OS)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- From randomization to the date of death (Up to approximately 93 months)
What was measured
Overall survival (OS) is defined as the time between the date of randomization and the date of death. OS will be censored on the last date a participant was known to be alive.
Analysis population: All concurrently randomized participants in Arm C and Arm B
Groups in this outcome
Arm B: Platinum Doublet Chemo
Participants receive investigator-choice of platinum doublet chemotherapy regimens in 3-week cycles up to a maximum of 3 cycles of IV chemotherapy (ie, 9 weeks of treatment; each cycle is 21 days). Following definitive surgery, participants could receive up to 4 cycles of adjuvant chemotherapy and/or radiation at the discretion of the investigator.
Arm C: Nivo 360 mg + Platinum Doublet Chemo
Participants receive nivolumab 360 mg IV + platinum doublet chemotherapy in 3-week cycles up to a maximum of 3 cycles of IV chemotherapy (ie, 9 weeks of treatment; each cycle is 21 days). Following definitive surgery, participants could receive up to 4 cycles of adjuvant chemotherapy and/or radiation at the discretion of the investigator.
| Group | Source count |
|---|---|
| Arm B: Platinum Doublet Chemo | 179 |
| Arm C: Nivo 360 mg + Platinum Doublet Chemo | 179 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Arm B: Platinum Doublet Chemo | 73.72 | Not reported | 47.34 | NA | Insufficient number of participants with events |
| Arm C: Nivo 360 mg + Platinum Doublet Chemo | NA | Not reported | NA | NA | Insufficient number of participants with events |
Complete source fields
- classes
- categories
- measurements
- comment
- Insufficient number of participants with events
- group Id
- OG000
- lower Limit
- 47.34
- upper Limit
- NA
- value
- 73.72
- comment
- Insufficient number of participants with events
- group Id
- OG001
- lower Limit
- NA
- upper Limit
- NA
- value
- NA
- denoms
- counts
- group Id
- OG000
- value
- 179
- group Id
- OG001
- value
- 179
- units
- Participants
- description
- Overall survival (OS) is defined as the time between the date of randomization and the date of death. OS will be censored on the last date a participant was known to be alive.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Participants receive investigator-choice of platinum doublet chemotherapy regimens in 3-week cycles up to a maximum of 3 cycles of IV chemotherapy (ie, 9 weeks of treatment; each cycle is 21 days). Following definitive surgery, participants could receive up to 4 cycles of adjuvant chemotherapy and/or radiation at the discretion of the investigator.
- id
- OG000
- title
- Arm B: Platinum Doublet Chemo
- description
- Participants receive nivolumab 360 mg IV + platinum doublet chemotherapy in 3-week cycles up to a maximum of 3 cycles of IV chemotherapy (ie, 9 weeks of treatment; each cycle is 21 days). Following definitive surgery, participants could receive up to 4 cycles of adjuvant chemotherapy and/or radiation at the discretion of the investigator.
- id
- OG001
- title
- Arm C: Nivo 360 mg + Platinum Doublet Chemo
- param Type
- MEDIAN
- population Description
- All concurrently randomized participants in Arm C and Arm B
- reporting Status
- POSTED
- time Frame
- From randomization to the date of death (Up to approximately 93 months)
- title
- Overall Survival (OS)
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice